Acadesina
Acadesina Uses, Dosage, Side Effects, Food Interaction and all others data.
Acadesina (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing coronary artery bypass graft (CABG) surgery. It is being developed jointly by PeriCor and Schering-Plough. Acadesina has been granted Orphan Drug Designation for B-CLL in the EU.
Acadesina has been shown to induce cell death apoptosis selectively in B-cells taken from healthy subjects and patients with B-CLL, with little effect on T-cells. As T-cells have an important role in fighting infection, it is anticipated that patients treated with acadesine will have a reduced risk of serious infections compared to those on current chemotherapies.
| Trade Name | Acadesina |
| Generic | Acadesine |
| Acadesine Other Names | Acadesina, Acadesine, Acadesinum, AICA-riboside |
| Type | |
| Formula | C9H14N4O5 |
| Weight | Average: 258.2313 Monoisotopic: 258.096419578 |
| Protein binding | Negligible (approximately 1%) |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in cardiac reperfusion injury, cardiovascular disorders, and coronary artery disease.
How Acadesina works
The mechanism by which acadesine selectively kills B-cells is not yet fully elucidated. The action of acadesine does not require the tumour suppressor protein p53 like other treatments. This is important, as p53 is often missing or defective in cancerous B-cells. Studies have shown acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes.
Half Life
1 week
Innovators Monograph
You find simplified version here Acadesina
